Phase 1 N=16 Shigella WRSS1 Vaccine Trial in Bangladesh
Diarrhea
Primary: Maximum Severity of Reactogenicity by Vaccination — 1; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=2,799 Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel
Shigellosis
Primary: Number of Participants With Adverse Events — 82; 61; 79; 64 participants
Phase 2 N=108 Phase 2 Shigella Vaccine and Challenge
Immunisation · Shigella Infection
Primary: The Proportion of Participants With Shigellosis Following Challenge With Shigella Sonnei 53G Through Day 63 in the Pooled Group of Participants Receiving Two Doses of…
Phase 1 N=82 Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults
Shigellosis
Primary: Maximum Reactogenicity Per Subject and Treatment Group — 5; 12; 9; 11 Participants
Phase 2 N=113 Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection
Shigellosis
Primary: Post-challenge Diarrhea, Fever, and Blood in Stool Adverse Events by Study Group — 1; 0; 4; 4 participants
N/A N=103 Safety Study of Live Attenuated Oral Shigella (WRSS1) Vaccine in Bangladeshi Adults and Children
Diarrhea
Primary: Number and Percentage of Participants With Serious Adverse Events (SAEs) — 0; 0; 1; 0 Participants
Phase 1 N=56 Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge Strain
Healthy
Primary: Number of Participants With Shigellosis — 0; 2; 1; 4 Participants
Phase 2 N=58 Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine
Shigella
Primary: Number of Participants With Moderate-Severe Shigellosis Illness, With Challenge — 14; 17 Participants
Phase 1 N=35 Controlled Human Infection Model Challenge/Rechallenge
Shigellosis
Primary: Percentage of Participants With Shigellosis Following Shigella Challenge — 59.1; 80.0; 15.8; 58.3 percentage of participants
N/A N=4,561 Chronic Gastrointestinal Sequelae of an Acute Outbreak of Bacterial Gastroenteritis in Walkerton Ontario
Irritable Bowel Syndrome
Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants
Phase 2 N=72 A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults
Shigella Sonnei Infection
Primary: Number of Subjects With Solicited Local and Systemic Adverse Reactions After Each Vaccination — 21; 25; 21; 21 Participants
Phase 2 N=71 A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Designed to Protect Against Infection With Shigella Sonnei in Healthy Adults
Dysentery, Bacillary
Primary: Percentage of Subjects With at Least One Episode of Shigellosis According to the Protocol Primary Case Definition — 46.9; 42.9 Percentage of subjects — p=0.4266
Phase 1 N=60 Efficacy of B7A BSIgG Against E. Coli Strain B7A Challenge
Healthy Volunteer
Primary: Safety of Serum Derived Bovine Immunoglobulins (BSIgG) — 1; 2; 0; 2 Participants
Phase 1 N=50 A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.
Shigellosis
Primary: Number of Subjects With Solicited Local Reaction After Any Vaccination — 8; 9; 8; 8 Participants
Phase 1 N=53 Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 1208S-122
Shigella Infection · Enterotoxigenic Escherichia Coli Infection
Primary: Participants Experiencing Fever, Diarrhea, or Dysentery; Solicited Local Adverse Events; Solicited Systemic Adverse Events; and Clinical Safety Laboratory Adverse Events…
Phase 2 N=20 Safety and Efficacy Study of WRSS1, a Shigella Sonnei Vaccine Candidate
Dysentery · Shigella · Diarrhea
Primary: Number of Participants With Adverse Events — 9; 5; 8; 10 Participants
N/A N=60 Improvements Through the Use of a Rapid Multiplex PCR Enteric Pathogen Detection Kit in Children With Hematochezia
Diarrhea Bloody
Primary: Blood Test Performance — 18; 17 Participants
Phase 1 N=38 Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR)
Shigellosis · Bacillary Dysentery
Primary: Number of Treatment Related Adverse Events — 27; 37; 41; 46 Adverse Events
Phase 1 N=27 CampETEC Hyperimmune Bovine Colostrum (HBC)
Healthy Volunteer
Primary: Incidence of Adverse Events — 1; 1; 0; 1 events
Phase 1 N=21 Effect of Bismuth Subsalicylate on the Gut Microbiome and Host Response in Healthy Adults
Healthy Adults
Primary: To Evaluate the Effect of BSS on the Human Gut Microbiome. — 2 Number of different bacterial taxa — p=<0.05
Phase 2 N=67 Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a
Shigellosis
Primary: Attack Rate of Shigellosis in Vaccinated Subjects. — 13; 18 Participants
Phase 1 N=13 Bacteriotherapy in Pediatric Inflammatory Bowel Disease
Inflammatory Bowel Disease · Crohn's Disease · Ulcerative Colitis
Primary: Number of Participants Who Responded to Stool Translplantation By 2 Weeks as Determined by Pediatric Ulcerative Colitis Activity Index (PUCAI)/Pediatric Crohn's Disease…
Phase 2 N=48 SH-DS01 on Fecal Metagenomic Stability
Irritable Bowel Syndrome
Primary: Safety and Tolerability of DS-01 Treatment vs Placebo — 0; 0 Participants
Phase 3 N=30 Efficacy of Rifaximin in Preventing Campylobacteriosis
Dysentery · Diarrhea · Enteric Campylobacteriosis
Primary: Campylobacteriosis — 13; 11 Participants
Phase 4 N=88 Efficacy of Lactobacillus GG With Diosmectite in Treatment Children With Acute Gastroenteritis
Diarrhea
Primary: Duration of Diarrhea — 2; 2 days — p=0.43
N/A N=83 Evaluation of Bacillus Subtilis R0179 in Healthy Young Adults
Healthy
Primary: Evaluation of the Effect of B. Subtilis R0179 on Wellness Questionnaires for GI Distress — 0.5; 0.3; 0.6; 0.7 units on a scale